MetaVia Inc. Set to Showcase Innovations at Key Conferences Focused on Cardiometabolic Diseases

MetaVia Inc. Set to Showcase Innovations at Key Conferences

MetaVia Inc., a clinical-stage biotechnology company listed on Nasdaq under MTVA, is poised for an impactful presence at several upcoming investor and industry conferences, emphasizing its commitment to combatging cardiometabolic diseases. With innovative treatments in the pipeline, the company aims to engage with stakeholders and investors, showcasing its advancements in this critical medical field.

Upcoming Events

1. Wells Fargo Healthcare Conference

Scheduled from September 3-5, this conference will convene in Boston, Massachusetts. Hyung Heon Kim, the President and CEO of MetaVia, will represent the company, presenting the latest advancements and opportunities in cardiometabolic health.

2. H.C. Wainwright 27th Annual Global Investment Conference

Taking place from September 8-10, Mr. Kim will participate in a fireside chat at this prestigious gathering. Notably, an on-demand presentation by MetaVia will be accessible starting September 5 at 7:00 AM ET. Institutional investors registered for the event are encouraged to log into the conference portal to schedule meetings with the management team.

3. Obesity Science Innovation 2025 Congress

On September 16-17, this event will focus on obesity, with Mr. Kim providing a detailed overview of the company's flagship product, DA-1726. This novel dual oxyntomodulin (OXM) analog agonist is designed to address both glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), representing a significant step forward in treating obesity.

4. Fierce Biotech Week

Mr. Kim will also attend Fierce Biotech Week from October 7-9 in Boston, further enhancing the disclosure of MetaVia's innovative research and potential impact on metabolic health.

Focus on DA-1726

DA-1726 stands out as a pioneering treatment within MetaVia's pipeline. This dual agonist has shown promise in clinical trials, particularly a Phase 1 multiple ascending dose (MAD) trial where it showcased best-in-class weight loss potential, enhanced glucose control, and waist reduction. The mechanism of action of DA-1726 involves mimicking naturally occurring gut hormones, leading to increased energy expenditure and decreased food intake, which may offer superior results compared to traditional therapies.

In addition to DA-1726, MetaVia is advancing DA-1241, a G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of crucial gut peptides such as GLP-1, GIP, and PYY. Early studies have indicated improvements in liver health, lipid metabolism, and overall glucose control, providing further optimism around the company's strategies to address metabolic dysfunction-related conditions.

Investment Opportunities

As MetaVia prepares for these conferences, potential investors and interested parties are encouraged to reach out for discussions regarding the company's trajectory and innovations. Meetings outside these events can be arranged through inquiries directed to Michael Miller, via email at [email protected].

Conclusion

MetaVia's participation in these upcoming conferences signifies its active role in transforming the landscape of cardiometabolic disease treatment. The scientific advancements represented by DA-1726 and DA-1241 highlight the company's dedication to addressing critical health challenges and improving patient outcomes. For more insights, updates, and event details, please visit www.metaviatx.com.